Inventiva S.A. ADR (IVA) Stock Price, Quote & News

Company Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 3 80 44 75 00

Website: inventivapharma.com

Address:

50 rue de Dijon, Daix, France

POPEYE832 Jun. 10 at 5:57 PM

$IVA Inventiva completed enrollment for its phase 3 trial on April 1, 2025. Phase 3 results are expected in 2026. If they are as good as those from phase 2B — which were better than Madrigal's — it could become a blockbuster!

0 · Reply

BioRich Jun. 5 at 3:12 PM

$ALT @Quantumup Reported. This is old news desperately presented as new. Amazing that you pump something that happened a year ago. How did that work out then, when there was still hope? How do you think it would work out better this time around? Likely just desperation to pump anything at this point to get this underperformer to move. Do better Q. Get that Gargage out of here. $MDGL $IVA $VKTX $AKRO ALGS ETNB Heads up to you too @VisionGT.

1 · Reply

Quantumup Jun. 5 at 2:28 PM

Citizens reiterated $ALT Market Outperform-$25 and said, "Altimmune's (ALT, MO, $25 PT) pemvidutide will be featured in an oral presentation on Saturday (6/22) highlighting cardio-inflammatory lipidomic analyses." $MDGL $IVA $VKTX ALGS $AKRO ETNB Citizens added, "While the abstract remains under embargo until June 13, $ALT has previously presented data showing pemvidutide reduced lipid species associated with systemic inflammation and CV disease in obese, non-diabetics. $ALT will present three posters on pemvidutide, focusing on its effectiveness in reducing visceral adipose tissue mass, its impact on cardiovascular risk, and its role in reverse cholesterol transport. The next key catalyst for $ALT shares is the Phase 2b IMPACT data in #MASH coming sometime this month."

0 · Reply

Quantumup Jun. 4 at 3:03 PM

Leerink reiterated $SGMT Outperform-$26 and said they believe denifanstat's +VE results in moderate-to-severe acne suggest an attractive clinical profile for both FASN inhibition in acne and #NASH. $ASCLF $MDGL $IVA $VKTX ALGS AKRO ETNB LLY NVO PFE Leerink, in its $SGMT note, said:

0 · Reply

Quantumup Jun. 2 at 12:34 PM

Stifel reiterated $ALT Buy-$18 and said, "We hosted $ALT management (President/CEO Vipin Garg, CMO Scott Harris, CFO Greg Weaver) as pemvidutide (GLP-1/GCG agonist) approaches its critical Ph.2b IMPACT readout for #MASH (expected June)." $MDGL $IVA $VKTX $ALGS AKRO ETNB Stifel went on to say:

0 · Reply

POPEYE832 May. 29 at 6:55 PM

"Hi all, does anyone have an opinion on #Inventiva $IVA? The company is awaiting Phase 3 results for lanifibranor in MASH. Phase 2b data looked stronger than resmetirom's. Thoughts?"

1 · Reply

Quantumup May. 14 at 12:05 PM

Piper Sandler reiterated $ALT Overweight-$25. $MDGL $IVA $VKTX $ALGS AKRO ETNB Piper Sandler said in its note:

2 · Reply

Armonica423 May. 10 at 4:58 PM

$IVA big week coming up this week for CYDY at cancer conferences, do your dd research

0 · Reply

Quantumup May. 2 at 2:45 PM

Cantor Fitzgerald⬇️the PT on $ETNB to $55 from $58 and reiterated at an Overweight, said "We remain Overweight on $ETNB following 1Q25 earnings, based on our thesis that pegozafermin will work in Phase 3 non-cirrhotic and cirrhotic #MASH." $MDGL $IVA $AKRO $ALGS ALT LLY NVO Cantor Fitzgerald added, "89bio expects to report topline results in Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) in 1Q26 (unchanged) and Phase 3 MASH studies with topline histology data from Phase 3 ENLIGHTEN-Fibrosis in F2/F3 MASH in 1H27 (unchanged) and Phase 3 ENLIGHTEN-Cirrhosis in compensated F4 MASH in 2028 (unchanged)."

0 · Reply

Quantumup Apr. 30 at 12:55 PM

Clear Street🏁 $AKRO Buy-$49, said "We initiate Akero coverage with a Buy rating and $49 PT." $MDGL $IVA ETNB $VKTX $ALGS LLY NVO Clear Street added, " $AKRO's sole clinical asset and FGF21R agonist, Efruxifermin (EFX), demonstrates best-in-class potential for MASH treatment with a high probability of success in ongoing P3 studies across F2-F3 (pre-cirrhosis, Synchrony-Histology) and F4 (cirrhosis, Synchrony-Outcomes) stages. EFX's superior efficacy vs. competitors in the F4 cirrhosis market, bolstered by statistically significant results, establishes clear differentiation. EFX's significant fibrosis improvement potential, promising cirrhosis data, and favorable risk-benefit profile create strategic value, positioning it competitively against emerging GLP1 therapies and the marketed drug Rezdiffra. Our bullish outlook is anchored in EFX's multifaceted advantages."

0 · Reply

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

May 23, 2025, 2:30 AM EDT - 5 weeks ago

Inventiva reports 2025 First Quarter Financial Information¹

May 23, 2025, 2:00 AM EDT - 5 weeks ago

Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025

May 5, 2025, 2:30 AM EDT - 7 weeks ago

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

Apr 30, 2025, 4:00 PM EDT - 2 months ago

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

Apr 24, 2025, 4:01 PM EDT - 2 months ago

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

Apr 15, 2025, 4:00 PM EDT - 2 months ago

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

Apr 1, 2025, 5:00 PM EDT - 3 months ago

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Mar 27, 2025, 10:50 AM EDT - 3 months ago

Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 4:00 PM EDT - 3 months ago

Inventiva reports its 2024 full year results and provides a business update

Mar 19, 2025, 4:00 PM EDT - 3 months ago

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Feb 26, 2025, 4:00 PM EST - 4 months ago

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Feb 20, 2025, 4:00 PM EST - 4 months ago

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Feb 10, 2025, 4:00 PM EST - 4 months ago

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Jan 29, 2025, 4:00 PM EST - 5 months ago

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

Jan 24, 2025, 4:00 PM EST - 5 months ago

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Jan 22, 2025, 4:00 PM EST - 5 months ago

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Dec 17, 2024, 4:00 PM EST - 6 months ago

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 2:30 AM EST - 6 months ago

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Dec 12, 2024, 4:00 PM EST - 7 months ago

Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024

Nov 21, 2024, 4:00 PM EST - 7 months ago

Inventiva reports 2024 Third Quarter Financial Information¹

Nov 20, 2024, 4:00 PM EST - 7 months ago

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Nov 18, 2024, 8:30 AM EST - 7 months ago

Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams

ALIT

Nov 15, 2024, 4:00 PM EST - 8 months ago

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Oct 30, 2024, 4:00 PM EDT - 8 months ago

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

Oct 21, 2024, 8:30 AM EDT - 8 months ago

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Oct 14, 2024, 1:45 PM EDT - 9 months ago

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Oct 14, 2024, 10:48 AM EDT - 9 months ago

Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?

Oct 14, 2024, 2:35 AM EDT - 9 months ago

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

Oct 14, 2024, 2:30 AM EDT - 9 months ago

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Sep 25, 2024, 4:00 PM EDT - 9 months ago

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

Jul 31, 2024, 4:00 PM EDT - 11 months ago

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

Jul 25, 2024, 4:00 PM EDT - 1 year ago

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

Jul 18, 2024, 2:30 AM EDT - 1 year ago

Inventiva announces a €20.1 million issuance of royalty certificates

Jul 8, 2024, 2:36 PM EDT - 1 year ago

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Jul 5, 2024, 4:00 PM EDT - 1 year ago

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

Jun 21, 2024, 4:00 PM EDT - 1 year ago

Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024

May 30, 2024, 2:30 AM EDT - 1 year ago

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

May 22, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

May 21, 2024, 4:00 PM EDT - 1 year ago

Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

May 16, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

May 13, 2024, 2:30 AM EDT - 1 year ago

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

Apr 3, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

Mar 28, 2024, 11:27 AM EDT - 1 year ago

Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 3:00 AM EDT - 1 year ago

Inventiva announces the nomination of Andre Turenne as Director

Mar 27, 2024, 4:00 PM EDT - 1 year ago

Inventiva reports its 2023 full-year results

Mar 22, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

Mar 18, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

Mar 13, 2024, 4:00 PM EDT - 1 year ago

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

Mar 7, 2024, 4:00 PM EST - 1 year ago

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

POPEYE832 Jun. 10 at 5:57 PM

0 · Reply

BioRich Jun. 5 at 3:12 PM

1 · Reply

Quantumup Jun. 5 at 2:28 PM

0 · Reply

Quantumup Jun. 4 at 3:03 PM

0 · Reply

Quantumup Jun. 2 at 12:34 PM

0 · Reply

POPEYE832 May. 29 at 6:55 PM

"Hi all, does anyone have an opinion on #Inventiva $IVA? The company is awaiting Phase 3 results for lanifibranor in MASH. Phase 2b data looked stronger than resmetirom's. Thoughts?"

1 · Reply

Quantumup May. 14 at 12:05 PM

Piper Sandler reiterated $ALT Overweight-$25. $MDGL $IVA $VKTX $ALGS AKRO ETNB Piper Sandler said in its note:

2 · Reply

Armonica423 May. 10 at 4:58 PM

$IVA big week coming up this week for CYDY at cancer conferences, do your dd research

0 · Reply

Quantumup May. 2 at 2:45 PM

0 · Reply

Quantumup Apr. 30 at 12:55 PM

0 · Reply

Quantumup Apr. 24 at 2:41 PM

Citizens JMP reiterated $MDGL Market Outperform-$443 after its Doctor of Medicine survey. $IVA $AKRO $ETNB $VKTX ALGS SGMT LLY ALT Citizens JMP said in its MD survey note: "Our physician survey confirms 1Q25 reimbursement seasonality with fewer patients on paid drug but projected long-term Rezdiffra use remains high and our first check on persistence is better than our modeled expectations."

0 · Reply

LienNP Apr. 22 at 1:51 PM

$IVA

0 · Reply

Avieira5 Apr. 21 at 4:17 PM

$IVA slow climb up on no volume! Accumulation but must not have my shares out there, tight float

0 · Reply

LienNP Apr. 11 at 4:07 PM

$IVA **Key Analyst Insights** - **Price Targets**: - *Average Target*: $12.40 to $13.67), implying **288–349% upside**. - *High/Low*: $20.00 (Stifel) to $3.00 (UBS). - **Median Target**: $11.50, suggesting a **261% potential increase** from the current price. - **Analyst Consensus**: - **Strong Buy** (7 analysts), with only 1 Hold rating (UBS). - Recent reiterations from HC Wainwright ($13) and Guggenheim ($9) highlight confidence in clinical progress.

0 · Reply

JarvisFlow Apr. 4 at 2:28 PM

Guggenheim has updated their rating for Inventiva ( $IVA ) to Buy with a price target of 9.

0 · Reply

Quantumup Apr. 4 at 12:20 PM

H.C. Wainwright reiterated $ALT Buy-$12, said "On March 24, Altimmune's CEO Vipin K. Garg and CMO M. Scott Harris, joined us for a virtual fireside Q&A session focused on pemvidutide, a glucagon-like peptide-1 (GLP-1) and glucagon dual receptor agonist, being developed in metabolic dysfunction-associated steatohepatitis (MASH), obesity, and two other high-impact indications: alcohol use disorder (AUD) and alcohol liver disease (ALD) (link to webcast). In addition, we hosted management for virtual investor meetings on March 26 and 27." $MDGL $IVA $VKTX $ALGS TERN AKRO ETNB H.C. Wainwright additionally said:

1 · Reply

Quantumup Apr. 4 at 12:03 PM

Guggenheim⬇️the PT on $IVA to $9 was $12 and reiterated at a Buy, said "We continue to view lani as the next and potentially best-in-class ORAL treatment for MASH fibrosis patients and MASH patients with T2D — we continue to recommend long-term investors BUY." $LLY MDGL $VKTX $ALGS $ALT AKRO ETNB Guggenheim said in it note to investors:

0 · Reply

JarvisFlow Apr. 2 at 5:26 PM

HC Wainwright & Co. has adjusted their stance on Inventiva ( $IVA ), setting the rating to Buy with a target price of 13.

0 · Reply

Quantumup Apr. 2 at 12:47 PM

Stifel reiterated $IVA Buy-$17 $LLY $MDGL $VKTX $ALGS ALT AKRO ETNB Stifel said in its note, "The culmination of a 4-year-long endeavor, $IVA finally announced the completion of enrollment in its Ph.3 NATiV3 trial, marking a significant milestone in lanifibranor/Lani's clinical development in MASH. NATIV3 ultimately exceeded enrollment targets, randomizing 1,009 patients into its main analysis cohort (F2-F3 fibrosis) and an additional 410 patients into its exploratory cohort (non-F2-F3 screen failures), the latter of which will provide supplemental non-invasive efficacy and safety data to support a regulatory submission. With multiple positive safety reviews from an independent DMC and a blinded interim review (Sep. 2024) indicating improving trends on multiple key biomarkers, we believe NATIV3 has a high likelihood to replicate the positive Ph.2b NATIVE trial-topline results are expected in 2H26. Stifel went on to say:

0 · Reply

Quantumup Apr. 2 at 11:24 AM

Citizens JMP reiterated $ALT Market Outperform-$25. $MDGL $IVA $VKTX $ALGS TERN ETNB AKRO Citizens JMP said in its note: "We are bullish on Phase 2b success for pemvidutide primarily due to the unprecedented reductions in liver fat which are the best correlates to histologic success in MASH, while the drug has also shown improvements in several other non-invasive markers associated with histologic response. Recall that Boehringers GLP/glucagon agonist survodutide led to a 21% fibrosis response and 35% MASH resolution response (both pbo-adj.) after 48 weeks that are near the top of the MASH landscape. Pemvidutide has better liver fat responses after week 24 than survodutide at week 48. The grand slam scenario for pemvidutide is hitting those marks in half the time with a better tolerability profile (which we think is a lock). Citizens JMP went on to say:

2 · Reply

G101SPM Mar. 31 at 7:43 PM

#SHOWTIME ^^ Kempen Life Sciences Conference (April 1-2) Scheduled to appear: $GLPG, $IVA, $QURE ^^ Sportradar Group AG Class A Investor Day (April 1) Scheduled to appear: $SRAD ^^ Western Midstream Partners, LP US Capital Advisors Midstream Corporate Access Day (April 1) Scheduled to appear: $WES

0 · Reply

Market Cap	291.77M
Revenue (ttm)	15.93M
Net Income (ttm)	-199.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,251.35%
Debt to Equity Ratio	-0.51

Volume	7,500
Avg Vol	21,762
Day's Range	N/A - N/A
Shares Out	95.66M
Stochastic %K	9%
Beta	0.75
Analysts	Strong Sell
Price Target	$10.86